LOAN AND SECURITY AGREEMENTLoan and Security Agreement • March 18th, 2019 • Aclaris Therapeutics, Inc. • Pharmaceutical preparations
THIS LOAN AND SECURITY AGREEMENT (as the same may from time to time be amended, modified, supplemented or restated, this “Agreement”) dated as of October 15, 2018 (the “Effective Date”) among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 133 North Fairfax Street, Alexandria, Virginia 22314 (“Oxford”), as collateral agent (in such capacity, “Collateral Agent”), the Lenders listed on Schedule 1.1 hereof or otherwise a party hereto from time to time including Oxford in its capacity as a Lender (each a “Lender” and collectively, the “Lenders”), and ACLARIS THERAPEUTICS, INC., a Delaware corporation (“Parent”) with offices located at 640 Lee Road, Suite 200, Wayne, PA 19087, Confluence Discovery Technologies, Inc., a Delaware corporation with offices located at 4320 Forest Park Avenue, Suite 303, St. Louis, MO 63108 (“CDT”) and ACLARIS LIFE SCIENCES, INC., a Delaware corporation with offices located at 4320 Forest Park Avenue, Suite 303, St. Louis, MO 63
FIRST AMENDMENT TO SUBLEASESublease • March 18th, 2019 • Aclaris Therapeutics, Inc. • Pharmaceutical preparations
This First Amendment to Sublease (this “Amendment”) dated as of this 13th day of December, 2017 by and between Aclaris Therapeutics, Inc., a Delaware corporation, with offices located at 101 Lindenwood Drive, Suite 400, Malvern, Pennsylvania 19355 (“Subtenant”), and Auxilium Pharmaceuticals, LLC, a Delaware limited liability company, with offices located at 1400 Atwater Drive, Malvern, PA 19355 (“Sublandlord”).
